AREX Biosciences, Ltd successfully participated in the 2025 AACR Annual Meeting, the world’s premier gathering for cancer researchers, clinicians, and biopharmaceutical professionals dedicated to advancing cancer prevention, diagnosis, and treatment.
During the meeting, our team engaged with attendees at Booth No. 4638, connecting with leading cancer researchers, laboratory scientists, and industry peers. We shared insights into our specialized solutions for cancer research and diagnostic applications, addressed technical inquiries, and discussed how our high-quality tools can support reliable, reproducible results in oncology studies and translational research workflows.
AREX’s portfolio for cancer research includes a range of robust solutions tailored to meet the demands of modern oncology studies, such as high-performance IHC antibodies (including raw and optimized tissue-specific series), the AREXVisual® System, micropolymer detection systems, chromogens, and supporting ancillaries. These products are developed to deliver consistent, sensitive performance for applications including tumor marker detection, biomarker validation, and immunohistochemistry-based research assays.
The 2025 AACR Annual Meeting provided a valuable platform for AREX to strengthen connections with the global cancer research community, gather direct feedback from researchers and clinicians, and align our product development with the evolving needs of cancer laboratories worldwide. We greatly appreciated the opportunity to learn from attendees’ groundbreaking work and explore collaborative opportunities to advance cancer research.
We sincerely thank all attendees, partners, and peers who visited our booth at the 2025 AACR Annual Meeting. For further information about AREX Biosciences’ cancer research and pathology solutions, please contact our team directly.
Post time: 2025-04-30 10:24:33
